Cheng Hui, Huang Chong Mei, Wang Yang, Hu Xiao Xia, Xu Xiao Qian, Song Xian Min, Tang Gu Sheng, Chen Li, Yang Jian Min
Institute of Hematology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.
Mol Biosyst. 2017 May 30;13(6):1102-1108. doi: 10.1039/c6mb00874g.
Acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) are common types of acute leukemia in adults and cause low survival rate and poor outcome after 5 years despite high rates of complete remission (CR) with modern chemotherapeutic regimens. To understand the distinct mechanisms in leukemogenesis for ALL and AML and to identify markers for diagnosis and treatment, lncRNA and mRNA expression profiles of AML and ALL patients and healthy controls were generated using microarray analysis. For comparison, the differentially expressed mRNA functions were annotated using gene ontology (GO) and pathway analysis. The microarray revealed that 1011 lncRNAs and 2656 mRNAs differed in AML patients and 6069 lncRNAs and 5338 mRNAs differed in ALL patients from those in healthy controls. The GO terms and KEGG pathway annotation data revealed that the olfactory receptor activity, G-protein coupled receptor activity and olfactory transduction-related genes were significantly associated with AML and ALL. Co-expression network analysis indicated that 108 lncRNAs and 85 mRNAs were included in the co-expression network. This study is the first to explore genome-wide lncRNA expression and co-expression with mRNA patterns in AML and ALL using microarray technology and could provide basic information for new biomarkers or treatment targets to alleviate AML and ALL.
急性淋巴细胞白血病(ALL)和急性髓系白血病(AML)是成人常见的急性白血病类型,尽管采用现代化疗方案可实现较高的完全缓解(CR)率,但5年后生存率较低且预后较差。为了解ALL和AML白血病发生的不同机制,并确定诊断和治疗标志物,我们使用微阵列分析生成了AML和ALL患者以及健康对照的lncRNA和mRNA表达谱。为进行比较,我们使用基因本体论(GO)和通路分析对差异表达的mRNA功能进行了注释。微阵列显示,与健康对照相比,AML患者中有1011个lncRNA和2656个mRNA存在差异,ALL患者中有6069个lncRNA和5338个mRNA存在差异。GO术语和KEGG通路注释数据显示,嗅觉受体活性、G蛋白偶联受体活性以及与嗅觉转导相关的基因与AML和ALL显著相关。共表达网络分析表明,共表达网络中包含108个lncRNA和85个mRNA。本研究首次使用微阵列技术探索AML和ALL中全基因组lncRNA表达以及与mRNA模式的共表达情况,可为缓解AML和ALL的新生物标志物或治疗靶点提供基础信息。